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To compare approaches for obtaining relative and absolute estimates of risk of 28-day COVID-19 




Three designs were compared. (A) case-cohort which does not explicitly account for the time-
changing prevalence of COVID-19 infection, (B) 28-day landmarking, a series of sequential 
overlapping sub-studies incorporating time-updating proxy measures of the prevalence of infection, 
and (C) daily landmarking. Regression models were fitted to predict 28-day COVID-19 mortality. 
 
Setting  
Working on behalf of NHS England, we used clinical data from adult patients from all regions of 
England held in the TPP SystmOne electronic health record system, linked to Office for National 
Statistics (ONS) mortality data, using the OpenSAFELY platform. 
 
Participants 
Eligible participants were adults aged 18 or over, registered at a general practice using TPP software 
on 1
st
 March 2020 with recorded sex, postcode and ethnicity. 11,972,947 individuals were included, 
and 7,999 participants experienced a COVID-19 related death. The study period lasted 100 days, 
ending 8
th
 June 2020. 
 
Predictors 
A range of demographic characteristics and comorbidities were used as potential predictors. Local 
infection prevalence was estimated with three proxies: modelled based on local prevalence and 
other key factors; rate of A&E COVID-19 related attendances; and rate of suspected COVID-19 cases 
in primary care. 
 
Main outcome measures  
COVID-19 related death. 
 
Results  
All models discriminated well between patients who did and did not experience COVID-19 related 
death, with C-statistics ranging from 0.92-0.94. Accurate estimates of absolute risk required data on 
local infection prevalence, with modelled estimates providing the best performance.  
 
Conclusions 
Reliable estimates of absolute risk need to incorporate changing local prevalence of infection. Simple 
models can provide very good discrimination and may simplify implementation of risk prediction 
tools in practice.      
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Within 9 months of being characterised as a pandemic by the World Health Organization1, cases of 
COVID-19 had reached almost 100 million globally and around 3.8 million in the UK, with more than 
2 million deaths attributed to the virus globally and 100,000 in the UK.2,3 Evolving policies regarding 
shielding, return-to-work guidance, prioritisation of vaccinations and individual choices about 
restricting social contact are heavily informed by estimated risk of severe outcomes from COVID-19. 
Here, we focus on risk prediction in the general population, in contrast to predicting prognosis 
among hospitalised or test-positive subgroups. Estimates of absolute risk are desirable to inform 
policy and public health decisions. However, transporting estimates of absolute risk from one 
context to another, such as a different time period or a different geographical region, is particularly 
challenging in COVID-19, due to the substantial variation in the prevalence of infection over time and 
by geography.
4
 Prediction models that do not explicitly model the underlying prevalence of infection 
are likely to produce poor absolute risk estimates. However, the prevalence of infection is not 
directly measured thus proxy measures must be used. Whether easily accessible proxy measures are 
sufficiently good to produce reasonable absolute and relative risk estimates remains uncertain.  
 
Early risk prediction models relating to COVID-19 outcomes were found to be poorly reported and at 
high risk of bias and over-optimism.
5
 However, two subsequent models have been developed to 
predict risk scores for COVID-19 death in the UK general population. The COVID-AGE is a risk score 
obtained by an algorithm derived by combining evidence from published studies.
6,7
 QCOVID is a 
prediction model estimated using routinely collected primary care data in the UK.8 Both of these risk 
prediction approaches met most criteria for low risk of bias in the development of risk prediction 
algorithms.9 However, neither of these algorithms involved explicit modelling of the underlying 
prevalence of COVID-19 infection, which limits the extent they could be adapted to provide accurate 
estimates of absolute risk for time periods or settings with different infection prevalences. 
 
In this study, we therefore used data held in the OpenSAFELY platform10 on almost 12 million adults 
in England to answer: 1) How well can we improve estimates of absolute risk of COVID-19 mortality 
by explicitly incorporating proxy estimates of the changing infection prevalence? 2) Do risk 
prediction models which do not explicitly model the underlying burden of infection produce a good 
ranking of people’s risk of COVID-19 mortality in different contexts (time and geographical)? 3) Can 
simpler prediction algorithms be used without losing substantial predictive ability, compared with 





Full details of the methods used can be found in our pre-published protocol.11  This manuscript 
follows the TRIPOD statement for prediction models.12  
 
Data Source 
Primary care records managed by the GP software provider TPP were linked to ONS death data 
through OpenSAFELY, a data analytics platform created by our team on behalf of NHS England to 
address urgent COVID-19 research questions (https://opensafely.org). OpenSAFELY provides a 
secure software interface allowing the analysis of pseudonymized primary care patient records from 
England in near real-time within the EHR vendor’s highly secure data centre, avoiding the need for 
large volumes of potentially disclosive pseudonymized patient data to be transferred off-site. This, in 
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addition to other technical and organisational controls, minimizes any risk of re-identification. 
Similarly pseudonymized datasets from other data providers are securely provided to the electronic 
health record vendor and linked to the primary care data. The full dataset within OpenSAFELY is 
based on 24 million people currently registered with GP surgeries using TPP SystmOne software. It 
includes pseudonymized data such as coded diagnoses, medications and physiological parameters. 
No free text data are included.  
 
Study Population  
 
The target population of interest is adults in England living in the community; residential settings are 
excluded since risks experienced in institutions such as care homes are likely to be very different to 
those in smaller households.  
 
The base cohort used in this study comprises males and females aged 18 years or older registered as 
of 1st March 2020 in a general practice employing the TPP system. Patients with missing age or a 
recorded age over 105 years, missing sex or missing postcode (from which household and 
geographic information is calculated) were excluded. Households of greater than 10 people were 
excluded. The study timeframe was the 100 day period beginning 1
st









The outcome to be predicted is 28-day risk of COVID-19 related death. Risk is predicted for the 
general community, rather than infected people, thus the risk being predicted combines the risk of 
infection and the risk of dying once infected. Primary care records held within the TPP system were 
linked to mortality data from the Office for National Statistics (ONS). COVID-19 related death was 
defined as a death with an ICD-10 code of U07.1 or U07.2 anywhere on the death certificate.  
 
Predictor variables  
 
We selected candidate predictors based on known or plausible associations with exposure to COVID-
19 infection, risk of severe illness or respiratory tract infection, and factors associated with 
healthcare access or level of care. Our data include diagnoses (Read 3 CTV3), prescriptions (dm+d), 
basic sociodemographics and vital signs. Briefly, potential predictors included:  age, sex, ethnicity, 
deprivation, number in household, presence of young children (under 12 years old) in household, a 
rural indicator, obesity, smoking and blood pressure. Comorbidities included: diagnosed 
hypertension, chronic heart disease, atrial fibrillation, surgery for peripheral arterial disease, deep 
vein thrombosis or pulmonary embolism, diabetes, stroke, dementia, other neurological conditions, 
asthma, respiratory disease, haematological and non-haematological malignancies, solid organ 
transplant, dialysis, poor kidney function, common autoimmune diseases, asplenia, other 
immunosuppressive conditions, inflammatory bowel disease, HIV, learning disability, serious mental 
illness, and fragility fracture in the last two years. Details and codelists are provided in the Appendix, 
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Proxy measures of the prevalence of COVID-19 infection  
 
Three different proxy measures of infection prevalence, measured daily, were considered. First, 
modelled estimates were obtained from dynamic disease modelling,13 with estimates obtained by 
region (7 regions in England) and by 5-year age-group. These estimates account for the infection 
prevalence, the way in which different age-groups interact with each other and the proportion of 
the population who are susceptible. These are estimates, thus come with uncertainty and potential 
error, neither of which is accounted for within our modelling. Second, the mean daily rate of COVID-
19 related A&E attendances over the last 7 days was estimated within each Sustainability and 
Transformation Partnership (STP; used as a measure of local geographic area). Rate of A&E 
attendances is likely to be an imperfect proxy since it is likely to lag behind true prevalence of 
infection. Third, the mean daily rate of suspected COVID-19 cases (with CTV3 Codes XaaNq, Y20cf, 
Y211b, Y22b7 and Y22b8 indicating a suspected case) in primary care over the last 7 days was 
estimated by STP.  A&E attendances and suspected cases in primary care are both likely to lag 
behind the true infection prevalence, although this will not necessarily hinder performance in 
predicting COVID-19 mortality. They may also be sensitive to changes in how and when people 




Three approaches were used: (A) a case-cohort study, (B) 28-day landmarking,14 and (C) daily 
landmarking. The first is a computationally efficient version of a traditional cohort design which does 
not explicitly model changes in the infection prevalence. The second involves creating multiple 
sequential overlapping 28-day sub-studies, allowing time-varying proxy measures of the infection 
prevalence to be explicitly incorporated into the risk prediction model. The third approach 
additionally updates the measures of the infection prevalence throughout the 28-day period, to try 
to better estimate the relationship between current infection prevalence and risk.  
 
For approach A, follow-up began 1st March 2020 and ended at the first of: COVID-19 related death or 
8
th
 June 2020. The outcome was COVID-19 related death. No censoring was applied at death due to 
non-COVID causes, because the target of inference was the sub-distribution hazard. The sub-
distribution hazard can be estimated by simply not censoring participants at the competing event 
because our only censoring event is the competing event of death due to other causes.15  The 
analysis sample included all cases of COVID-19 related death and a random age-stratified sample of 
the eligible patient population (the ‘sub-cohort’, largely comprising non-cases but likely to contain 
some cases by chance),
16,17
 with sampling fractions of 0.01 in the age-group 18-<40, 0.02 in 40-<60, 
0.025 in 60-<70, 0.05 in 70-<80 and 0.13 in 80+ years.  
 
For approach B, a series of 73 overlapping sequential sub-studies were extracted from the base 
cohort. The sub-studies started 0, 1, 2, 3, 4…, 72 days after 1st March 2020 and each sub-study 
continued for exactly 28 days. The first sub-study began on 1st March and the last began on 12th May 
2020 (Figure 1). All patients from the base cohort still alive at sub-study start were eligible to 
participate in that sub-study. Follow-up started at sub-study entry date and ended at the first of 
COVID-19 related death or 28 days after sub-study entry. Participants were not censored at deaths 
due to other causes. The outcome was COVID-19 related death during the 28 day period. Each sub-
study had a case-cohort design, including all eligible patients who experienced a COVID-19 related 
death during the 28-day sub-study period as cases and an age-stratified random sample of sub-study 
eligible patients (the sub-study sub-cohort), with age-group specific sampling fractions equal to 1/70 
of the sampling fractions for approach A (e.g. 0.01/70 = 0.00014 in the age-group 18-<40). Data from 
the 73 sub-studies were combined for analysis. Predictor variables and proxy measures of the 
infection prevalence were assessed at day 0 of each sub-study. 
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Approach C also used a series of stacked sub-studies, with each lasting a single day. Thus 100 sub-
studies were formed, the first starting on 1
st 
March 2020 and the last starting on 8
th 
June 2020. Each 
sub-study included all cases (COVID-19 related deaths) occurring on that day and a random age-
stratified sample of non-cases who remained alive by the previous day, with sampling fractions 
equal to 1/100 of the sampling fractions for approach A. The outcome was the binary outcome of 
whether or not the sub-study participant experienced a COVID-19 related death on that day. This 
approach also required information about the daily rate of death due to other causes, which was 
estimated in a second case-cohort sample, comprising a sampling fraction of 0.3 of all non-COVID-19 
related deaths on each day and an age-stratified sample of participants who did not die of non-
COVID-19 related causes on that day, with sampling fractions equal to 1/100 of the sampling 





Variable selection was undertaken from the set of candidate predictors using a penalised regression 
approach (lasso)
18
. Functional forms for the proxy measures of burden of disease were selected 
using Akaike’s Information Criterion, as detailed in the protocol.11 
 
For approach A, a Cox proportional hazards model was fitted using time in study as the timescale 
including predictors selected by the lasso. Barlow weights with robust standard errors were used to 
account for the case-cohort design.16,17 Sub-cohort participants were weighted by the inverse of the 
sampling fraction and cases (COVID-19-related deaths) received a weight of 1 on the day they died 
and, unless they were also in the sub-cohort, a weight of zero prior to that. Royston-Parmar, Weibull 
and Generalised gamma models were also fitted. Results from these models are not shown: the 
Royston-Parmar models had very similar performance to the Cox models but the Weibull and 
Gamma models generally had poorer calibration. Note that these approach A models do not include 
any time-varying predictors or time-varying measures of prevalence of infection. 
 
For approach B, data from all 73 sub-studies were stacked to form one analysis dataset, with a 
variable indicating the sub-study (k=1,2,…,73). A Poisson model for 28-day COVID-19 related death 
was fitted using Barlow weights with robust standard errors, incorporating predictors selected by 
the lasso and proxy measures of the burden of infection. Three sets of models were fitted: one for 
each of the three proxy measures. Weibull and logistic models were also fitted. Results from these 
models are not shown but performance was very similar to that of the Poisson. 
 
For approach C, the series of 1-day studies were stacked to form one analysis dataset. A Poisson 
model was fitted to estimate the daily rate of COVID-19 related death using inverse sampling 
weights with robust standard errors, incorporating predictors selected by the lasso and proxy 
measures of the burden of infection. A similar Poisson model was fitted to estimate the daily rate of 
mortality due to non-COVID-19-related causes conditional on the same set of predictor variables, 
but without the measures of the burden of infection, weighted according to the inverse of the 
sampling fractions. Risk of 28-day COVID-19 related death was estimated by combining the 




The analysis was restricted to participants with recorded ethnicity data (which excluded 3,926,870 
participants, approximately 26%). Participants with missing BMI were assumed non-obese and 
participants with no smoking information were assumed to be non-smokers, on the assumption that 
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smoking and obesity, if present, are likely to be recorded. Patients with no serum creatinine 
measurement were included in the “no evidence of poor kidney function” group. Patients with 
diabetes but no glycosylated hemoglobin (HbA1c) measurement were included in a separate 





Three validation periods were considered, chosen to cover periods of higher and lower infection 
prevalence, within the period of time used for model development. Validation period 1 ran from 1st 
March to 28th March 2020, validation period 2 ran from 6th April to 3rd May 2020, validation period 3 
ran from 12th May to 8th June 2020 (Figure 2). Internal validation was undertaken in each of these 
periods, assessing performance within the data the models were developed on. Geographical and 
temporal internal-external validation were also undertaken.19 For the geographical internal-external 
validation, a leave-one-out approach was used using the 7 regions of England, omitting all 
participants from one geographical region in turn, performing the model selection and fitting the 
model in the sub-sample excluding that region, and then using the fitted model, applied to the local 
prevalence measures in the omitted region for approaches B and C, to make predictions for the 
participants in the omitted region. This was repeated for each of seven regions. For the temporal 
internal-external validation, the data were split into two time-periods: 1st March 2020 until 11th May 
and 12
th
 May until 8
th
 June 2020. For each validation period, all eligible participants who remained 
alive at the start of the period were included in the validation. Risks of 28-day COVID-19 related 
death were predicted using each model, using predictors and proxy measures of infection 
prevalence (where used) from the start of the validation period. Model performance was reported 
by comparing the observed outcome, 28-day COVID-19 related death, to the predicted risk.  
 
Discrimination – the ability to distinguish between cases (COVID-19 related deaths) and non-cases – 
was assessed by Harrell’s C-statistic, expressed as a percentage.20,21 The C-statistic estimates the 
probability that, if a case and non-case are randomly selected, the predicted risk will be higher for 
the case than the non-case. A completely uninformative prediction would have a C-statistic of 50% 
and a perfect prediction would have a C-statistic of 100%. Calibration – the agreement between 
observed outcomes and predictions – was assessed by (i) comparing mean predicted risk with mean 
observed risk, (ii) by estimating the calibration intercept and slope, with 95% confidence intervals, to 
assess whether models over- or under-estimate risk.
21,22
 The calibration intercept estimates the 
mean difference between observed and predicted risks, with intercepts less than zero indicating 
over-prediction on average and intercepts greater than zero indicating under-prediction. The 
calibration slope estimates the relationship between the log-odds of the observed risk and the log-
odds of the predicted risk, with slopes greater than one indicating that risk is under-estimated in 
high risk and over-estimated in low risk participants; the opposite holds for slopes of less than one. 
We reported model performance overall and within sex and broad age-group (18-<70, 70-<80 and 
80+). Insufficient events occurred in the youngest age-group to split further. 
 
A pre-specified analysis, described in the protocol, was to compare performance of the lasso-
selected models to models including fewer potential predictors. We considered: (i) a model including 
only age-group (10 categories: <40, 40-49, 50-59, 60-64, 65-69, 70-74, 75-79, 80-84, 85-89, 90+), sex 
and their interaction; (ii) number of comorbidities (0, 1, 2, 3+), sex, age-group, with all three-way 





 For approach B models, the proxy measures of burden of infection were 
additionally included.   
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The comorbidities included in the “number of comorbidities” variable for model (ii) were: respiratory 
disease, cystic fibrosis, severe asthma (with OCS use), chronic cardiac disease, atrial fibrillation, deep 
vein thrombosis or pulmonary embolism, surgery for arterial disease, diabetes, cancer diagnosed in 
the last year, haematological malignancy diagnosed within 5 years, liver disease, stroke, dementia, 
neurological disease, poor kidney function (eGFR <60 mL/min/1.73m
2
), dialysis, organ transplant, 
asplenia, condition inducing immunosuppression, HIV, and either obese or underweight.   
 
For the COVID-AGE risk tool, we could not reliably distinguish Type I from Type II diabetes so 
included all diabetes as Type II. We did not have an indicator of heart failure but included chronic 
cardiac disease. COVID-AGE is primarily a risk stratification tool, rather than intended to estimate 
absolute risks, so we did not estimate calibration measures for this tool.  
 
We also fitted a richer model including all candidate predictors without any variable selection, with 
all interactions with age (linear) and sex and additional spline terms for age.  
 
Software and reproducibility 
 
Data management was performed using Python and Google BigQuery, with analysis carried out using 
Stata 16.1 / Python. All of the code used for data management and analyses is openly shared online 




Patient and Public Involvement 
 
We have developed a publicly available website https://opensafely.org/ through which we invite any 







Table 1 described the base cohort used in these analyses, comprising almost 12 million patients of 
whom 7,999 experienced a COVID-19 related death. The case-cohort sample used for approach A 
included all 7,999 COVID-19 related deaths and a sub-cohort of 319,917, which contained 683 of the 
COVID-19 related deaths. The stacked landmark studies included all 7,999 COVID-19 deaths and 
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Table 1. Description of cohort used for model development  
 N (%) COVID-19 related 
deaths (%) 
Total 11,972,947 (100.0) 7,999 (0.07) 
Age-group:   
  18-39 4,275,852 (35.7) 52 (0.00) 
  40-49 2,022,527 (16.9) 141 (0.01) 
  50-59 2,040,181 (17.0) 437 (0.02) 
  60-69 1,635,143 (13.7) 938 (0.06) 
  70-79 1,319,367 (11.0) 2,025 (0.15) 
  80+ 6,798,77 (5.7) 4,406 (0.65) 
Sex:   
  Female 6,232,725 (52.1) 3,315 (0.05) 
  Male 5,740,222 (47.9) 4,684 (0.08) 
BMI:   
  Underweight (<18.5)  249,294 (2.1) 306 (0.12) 
  No evidence of underweight/obesity 3,982,133 (33.3) 2,480 (0.06) 
  Obese I (30-34.9)   3,690,583 (30.8) 2,430 (0.07) 
  Obese II (35-39.9)  1,794,812 (15.0) 1,462 (0.08) 
  Obese III (40+) 678,109 (5.7) 658 (0.10) 
  Missing 1,242,341 (10.4) 340 (0.03) 
Smoking:   
  Never smoker 5,540,732 (46.3) 2,499 (0.05) 
  Former smoker 3,921,016 (32.7) 4,745 (0.12) 
  Current smoker 2,253,231 (18.8) 737 (0.03) 
  Missing  257,968 (2.2) 18 (0.01) 
Ethnicity:   
White 10,184,871 (85.1) 6,952 (0.07) 
Indian 405,477 (3.4) 299 (0.07) 
Pakistani 262,882 (2.2) 161 (0.06) 
Bangladeshi/Other Asian 262,882 (2.2) 161 (0.06) 
African/Other black 280,466 (2.3) 173 (0.06) 
Caribbean 80,863 (0.7) 124 (0.15) 
Chinese 103,423 (0.9) 20 (0.02) 
Mixed/Other 392,097 (3.3) 147 (0.04) 
Deprivation:   
IMD 1 (least deprived) 2,315,449 (19.3) 1,255 (0.05) 
IMD 2 2,375,974 (19.8) 1,443 (0.06) 
IMD 3 2,398,815 (20.0) 1,537 (0.06) 
IMD 4 2,489,997 (20.8) 1,791 (0.07) 
IMD 5 (most deprived) 2,392,712 (20.0) 1,973 (0.08) 
Location:   
Urban 9,595,617 (80.1) 6,775 (0.07) 
Rural 2,377,330 (19.9) 1,224 (0.05) 
Region:   
East 2,730,203 (22.8)     1773 (0.06) 
London 1,018,332 (8.5)      755 (0.07) 
Midlands 2,673,963 (22.3)        2005 (0.07) 
North East and Yorkshire 2,242,375 (18.7)        1679 (0.07) 
North West 1,053,537 (8.8)        905 (0.09) 
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South East 744,930 (6.2)      309 (0.04) 
South West 1,509,607 (12.6)       573 (0.04) 
Blood pressure:   
Normal 2,797,632 (23.4) 1,725 (0.06) 
Elevated 1,757,455 (14.7) 1,406 (0.08) 
High, stage I 3,899,203 (32.6) 2,454 (0.06) 
High, stage II 2,492,161 (20.8) 2,389 (0.10) 
Missing 1,026,496 (8.6) 25 (0.00) 
Diagnosed hypertension 2,448,605 (20.5) 5,332 (0.22) 
   
Comorbidities   
Respiratory   
Asthma, no OCS use 1,829,710 (15.3) 1,008 (0.06) 
Asthma, with OCS use 112,407 (0.9) 248 (0.22) 
Respiratory disease 495,699 (4.1) 1,809 (0.36) 
Cystic Fibrosis or other conditions 3,167 (0.0) 4 (0.13) 
Cardiovascular   
Cardiac disease 783,896 (6.5) 3,008 (0.38) 
Atrial Fibrillation 430,798 (3.6) 1,808 (0.42) 
DVT/PE 249,969 (2.1) 773 (0.31) 
PAD or lower limb amputation 41,362 (0.3) 220 (0.53) 
Diabetes, controlled 738,369 (6.2) 1,908 (0.26) 
Diabetes, uncontrolled 346,726 (2.9) 1,054 (0.30) 
Diabetes, status unknown 133,387 (1.1) 306 (0.23) 
Neurological   
Stroke 240,401 (2.0) 1,287 (0.54) 
Vascular dementia 22,792 (0.2) 489 (2.15) 
Other neurological condition 114,431 (1.0) 480 (0.42) 
Cancer (non-haematological)   
Diagnosed <1 year ago 54,290 (0.5) 216 (0.40) 
Diagnosed 2-5 years ago 157,859 (1.3) 358 (0.23) 
Diagnosed 5+ years ago 362,457 (3.0) 879 (0.24) 
Haematological cancer   
Diagnosed <1 year ago 6,151 (0.1) 47 (0.76) 
Diagnosed 2-5 years ago 18,722 (0.2) 95 (0.51) 
Diagnosed 5+ years ago 42,492 (0.4) 116 (0.27) 
Kidney and liver   
Reduced kidney function  
(eGFR in range 30-<60 mL/min/1.73m2) 
607,308 (5.1) 2,793 (0.46) 
Very reduced kidney function 
(eGFR <30 mL/min/1.73m2) 
58,081 (0.5) 694 (1.19) 
Dialysis 8,871 (0.1) 115 (1.30) 
Liver disease 74,193 (0.6) 189 (0.25) 
Organ transplant 11,349 (0.1) 50 (0.44) 
Immunosuppression   
Spleen 19,815 (0.2) 29 (0.15) 
RA/SLE/Psoriasis 609,421 (5.1) 733 (0.12) 
Immunosuppression 13,091 (0.1) 28 (0.21) 
HIV 23,078 (0.2) 17 (0.07) 
Inflammatory bowel disease 152,080 (1.3) 169 (0.11) 
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Other   
Fracture (in >65 year old in last 2 years) 55,952 (0.5) 443 (0.79) 
Learning disability 158,350 (1.3) 161 (0.10) 




Table 2 shows measures of model performance in predicting 28-day risk in the three 28-day 
validation periods. Estimated model coefficients are provided in the appendix. For all models in all 
validation periods, the C-statistic was high (92-94%), indicating excellent ability to distinguish 
between cases and non-cases. For approach A, the Cox model, which did not explicitly model the 
prevalence of infection, the mean predicted and observed risks were very similar in the first 
validation period, but different in the second and third. In validation period 2, the mean observed 
risk was ten times higher than in validation period 1, but the mean predicted risk using approach A 
was (by design) the same for all three periods. The poor calibration in validation periods 2 and 3 was 
also reflected in high calibration intercepts.  
 
For the approach B model incorporating the modelled estimates of infection prevalence, the mean 
and observed risks were very similar in all three validation periods. The calibration intercept was 
slightly less than zero in validation periods 1 and 3, indicating slight over-estimation on average, with 
calibration slopes close to one, indicating reasonable calibration. Replacing the modelled estimates 
by either the rate of A&E COVID-19 attendances or the rate of suspected COVID-19 cases in primary 
care resulted in poorer calibration, particularly in the first validation period which had a very low 
infection prevalence. All approach B models had worse calibration than the approach A Cox model in 
validation period 1, the data on which the models are fitted, but considerably better calibration than 
the approach A model in the other two validation periods. All approach B models had very high 
discrimination, with C-statistics (92-94%). 
 
Approach C models performed similarly to approach B when using the actual measures of infection 
prevalence through the 28 day period. However, poor estimation of the measure using only data 
available at day 0 of the period led, in some cases, to large under- and over-estimation of risks (Table 
A3). 
 
The internal-external validation showed that the performance of the approach A Cox model was 
insensitive to the removal of a region or period of time (Appendix Figure A1). Approach B models 
were more sensitive to geographical or temporal omissions. 
 
Among the oldest age group (80+ years), discrimination was substantially lower than in the younger 
age-groups, reflecting the substantial discrimination that comes simply from age. Generally, 
discrimination was a little lower among males. The comparison of the discrimination by models that 
considered few versus many potential predictors, found that a simple model including only age and 
sex still provided fairly good discrimination (~80%) among the 18-<70 age-group, but was 
substantially worse for  the two older age-groups. In all cases, the model including the number of 
comorbidities, rather than a large number of indicators of individual comorbidities, performed 
almost as well as the models that considered many more predictors. COVID-AGE, which we applied 
only for approach A, performed similarly to the most complex models used.  
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Table 2. Measures of model performance in predicting 28-day risk of COVID-19 mortality 




















1 92.4 0.0038 0.0038 0.00 (-0.10, 0.09) 0.95 (0.86, 1.05) 
2 93.4 0.0374 0.0038 2.30 (2.27, 2.32) 1.02 (0.99, 1.05) 







1 92.5 0.0038 0.0044 -0.15 (-0.24, -0.06) 0.93 (0.84, 1.02) 
2 93.7 0.0374 0.0354 0.06 (0.03, 0.09) 1.00 (0.97, 1.03) 







1 92.1 0.0038 0.0145 -1.34 (-1.43, -1.25) 0.92 (0.83, 1.02) 
2 93.3 0.0374 0.0420 -0.12 (-0.15, -0.09) 0.99 (0.96, 1.02) 




primary care  
Poisson 
 
1 92.1 0.0038 0.0085 -0.80 (-0.89, -0.71) 0.90 (0.81, 1.00) 
2 93.5 0.0374 0.0378 -0.01 (-0.04, 0.02) 1.00 (0.97, 1.03) 
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We have developed and validated a risk prediction model for COVID-19 mortality in the general 
population with very high discrimination which can be applied within primary care electronic health 
record (EHR) systems without requiring linkage to external data, allowing accurate prediction of 
relative risk. In addition, we have developed a second set of models that enable estimation of 
absolute risk by incorporating estimates of the prevalence of COVID-19 infection. Incorporating 
modelled estimates led to the best model performance, but this may be impractical for most 
situations due to the complex modelling required to obtain these estimates. Incorporating the rate 
of suspected COVID-19 cases in local primary care practices led to reasonable model performance; 
this rate could be quantified within EHR systems in an automated manner, providing timely absolute 
risk estimates as the pandemic evolves.  Finally, our third set of models using daily landmarking 
allow estimation and comparison of absolute COVID-19 mortality risks under various scenarios (e.g. 
drastically increasing infection rates versus gradual decrease).  
 
We found that the existing COVID-AGE tool6,7 had very high discrimination, similar to the best 
performing models considered, suggesting this provides a reliable ranking of COVID-19 mortality 
risk. Interestingly, very simple models including only age, sex, ethnicity, a rural indicator, and a count 
of total comorbidities led to models with very good discrimination. When focusing on specific 
patient groups with higher morbidity, more complex models may provide useful additional 
discrimination, but in many cases much simpler models are able to discriminate well.  
 
In extending our knowledge of which approaches to use in predicting related COVID-19 death from a 
general population to inform future policies, this study has three major strengths. First, this is the 
first risk prediction algorithm that incorporates time-varying estimates of infection burden to 
provide accurate estimates of the absolute risk of COVID-19 related death. Second, the study uses 
data from a large representative sample of the general population. Third, we consider three 
different designs, several alternative estimation approaches, and contrast different ways of selecting 
predictors. 
 
 This study also has important weaknesses. First, the COVID-19 pandemic is evolving rapidly. We will 
re-validate and, if necessary, re-calibrate our models using data from the more recent wave, 
particularly in light of evidence suggesting differences in mortality with the new variant. Further, as 
the vaccines are rolled out, risk in the population will additionally depend on proportions of different 
patient groups vaccinated; this could be incorporated into subsequent iterations of these models.  
We have not yet externally validated these models. However, our internal-external validation 
suggests little over-optimism in the measures of model performance. 
 
Electronic health record data are not collected for research, so information on certain characteristics 
can be incomplete or absent. For example, ascertainment of HIV and cystic fibrosis is likely to be 
poor and pregnancy cannot easily be identified, limiting the ability to distinguish risks between these 
groups.  
 
Our approach to missing data reflected the way in which these models might be used in practice if 
applied within electronic health record systems. For example, patients with no BMI measurement 
would be assumed to have normal BMI. Our measures of model performance reflect performance 
under this implementation. The exception is ethnicity – given the strong relationships previously 
observed between ethnicity and COVID-19 outcomes we chose to restrict our sample to those with 
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recorded ethnicity. In previous work, model estimates from similar models were similar in ethnicity-
complete-case samples and following multiple imputation.10  
 
We have explored risk prediction for COVID-19 death in the general population. In some 
circumstances, the risk of COVID-19 death given infection with the virus might be of interest, and 
this could not be estimated with the present data in the absence of representative COVID-19 testing 
data. However, risk within the general population is more useful for various policy decisions, such as 
vaccine prioritisation.  
 
We did not attempt to compare the performance of our risk prediction models to QCOVID,6 because 
our database does not include all data required to implement that algorithm at present. In 
comparison to QCOVID, our algorithm used a smaller set of potential predictors. For example, we did 
not include homelessness as a predictor. Further, we restricted our sample to adults living in the 
community, so our risk predictions are not valid for those living in residential care. QCOVID reported 
a C-statistic of 93%; our models ranged from 92 to 94%.  
 
Our results have a number of implications for policy makers and GPs advising patients. Most of the 
discriminating power in each model evaluated here was driven by simple features such as age, sex 
and a count of co-morbidities. Complex risk prediction models driven by multiple variables from 
diverse sources can be difficult, slow, and expensive to implement in routine care: the cost, 
opportunity costs and complexity of such implementations may not be warranted. The fact that very 
simple models produce very high discrimination also suggests that policies targeting population level 
reduction of COVID-19 mortality risk may not need to distinguish between all comorbidities in detail. 
For certain policy decisions, such as vaccine prioritisation, this simplicity would provide a great 
advantage, with simple eligibility criteria resulting in faster programme rollout and delivery of 
vaccines. 
 
When absolute risk estimates are obtained from algorithms that do not explicitly model the 
prevalence of infection it is important to consider the context that data were collected in, in order to 
avoid misleading interpretations of absolute risk estimates. Our validated landmarking models can 
avoid such problems by providing absolute risk estimates which explicitly account for rapidly 
changing infection levels.  
 
Risk scores in COVID-19 need to be a dynamic and open process undergoing regular transparent re-
calibration rather than a single "one-off" digital commodity. We have developed a completely open 
source, transparent and freely available set of risk prediction models for COVID-19 mortality. Our 
approach accounts for rapid changes in the estimates of infection burden, due to daily changes in for 
example the number of people vaccinated, and therefore provide accurate estimates of the absolute 
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teams at NHS England / NHSX. We thank Professor Rafael Perera, Nuffield Department of Primary 
Care Health Science, for useful comments. 
 
Data Sharing  
All data were linked, stored and analysed securely within the OpenSAFELY platform 
https://opensafely.org/. Data include pseudonymized data such as coded diagnoses, medications 
and physiological parameters. No free text data are included. Detailed pseudonymised patient data 
is potentially re-identifiable and therefore not shared. We rapidly delivered the OpenSAFELY data 
analysis platform without prior funding to deliver timely analyses on urgent research questions in 
the context of the global Covid-19 health emergency: now that the platform is established we are 
developing a formal process for external users to request access in collaboration with NHS England; 
details of this process will be published shortly on https://opensafely.org/.  
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Figure 1. Schematic showing the design of the 28-day landmarking sub-studies (approach B) 
 
Figure 2. Schematic showing the internal and internal-external validation undertaken 
 
Figure 3. C-statistics for a range of models using modelling approach A and B, with the latter 
incorporating modelled estimates of the COVID-19 infection prevalence (ME), rates of A&E 
COVID-19 attendance (AE) and suspected COVID-19 rates in primary care (GP). Models 
shown are: Age and sex only, model including comorbidities via the total number only, the 
COVID-AGE tool, the main selected model, and a richer model including all variables. The 
three points within each graph, for each approach, show the three validation periods, 
differentiated by depth of colour (deepest = validation period 1, lightest = validation period 
3). 
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